english.prescrire.org > Spotlight > Archives : 2018 > Pembrolizumab (Keytruda°) in Hodgkin lymphoma with no further treatment options

Spotlight: Archives

Every month, the subjects in Prescrire’s Spotlight.

2018 : 1 | 30 | 60

In the July/August issue of Prescrire International: pembrolizumab (Keytruda°) in Hodgkin lymphoma with no further treatment options

FREE DOWNLOAD The immunostimulatory anti-PD-1 antibody pembrolizumab (Keytruda°) has been authorised in the European Union for patients with relapsed or refractory Hodgkin lymphoma, in spite of inadequate premarketing assessment.
Full text available for free download.

Summary

  • Pembrolizumab  has been authorised for patients with Hodgkin lymphoma after failure of an autologous haemopoietic stem cell transplant and brentuximab vedotin; or after failure of brentuximab vedotin alone when autologous haemopoietic stem cell transplantation is not an option.
     
  •  NOT ACCEPTABLE  An evaluation just as inadequate as that of nivolumab in Hodgkin lymphoma, mainly based on a single, short, non-comparative trial using surrogate endpoints. Pembrolizumab has many, sometimes serious, adverse effects.

Full text available for free download.

 ©Prescrire 1 July 2018

"Pembrolizumab (Keytruda°) in Hodgkin lymphoma with no further treatment options" Prescrire Int 2018; 27 (194): 177. (Pdf, free)

Share Share on Facebook Share on Twitter

 

Download the full review
Pdf, free

Prescrire's rating:
Prescrire's rating
 NOT ACCEPTABLE